ArticlePloS one2026
Factors associated with low-level viremia in people living with HIV: A 10-year retrospective study in South Korea.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe goal of antiretroviral therapy is to achieve and sustain the suppression of human immunodeficiency virus (HIV) viral load. In this study, we aimed to identify risk factors for low-level viremia (LLV) and examine their association with clinical outcomes in South Korea.
methodsWe retrospectively reviewed the medical records of patients with human immunodeficiency virus infection registered at Seoul Medical Center and Hallym University Sacred Heart Hospital between 2014 and 2023. LLV was defined as at least two consecutive HIV RNA measurements of 40-199 copies/mL taken more than 4 weeks apart. Patients with LLV were compared with those who maintained virological suppression (viral load < 40 copies/mL).
resultsOf the 381 patients included in the analysis, 15 (3.94%) experienced LLV. Compared with patients who maintained virological suppression, patients with LLV more frequently had an initial viral load ≥ 500,000 copies/mL (P < 0.01). No significant differences were observed between the groups in the rates of virological rebound, new-onset acquired immune deficiency syndrome-defining conditions, or mortality. Multivariable logistic regression identified an initial viral load ≥ 500,000 copies/mL as an independent risk factor for LLV (adjusted odds ratio, 4.735; 95% confidence interval, 1.505-14.897).
conclusionA high viral load was a significant risk factor for LLV. Large multicenter studies are required to further investigate risk factors and clinical implications of LLV in people living with HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.